SynthesisReproductive biology and endocrinology : RB&E2026
Does obesity affect serum anti-müllerian hormone or inhibin B levels in polycystic ovary syndrome? Results of a systematic review and meta-analysis.
Synthesis in Reproductive biology and endocrinology : RB&E, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAnti-Müllerian hormone (AMH) and inhibin B (INHB) are validated ovarian reserve biomarkers with key roles in polycystic ovary syndrome (PCOS) pathogenesis. Serum AMH has specific diagnostic value for PCOS, yet their differential expression and clinical significance in obese versus non-obese PCOS phenotypes remain unclear. To fill this gap, we performed the first systematic review and meta-analysis comparing serum AMH and INHB levels between obese and non-obese women with PCOS, and explored heterogeneity sources.
methodsThirty-eight observational studies (n = 15,003) were systematically retrieved and quality-assessed via the Newcastle-Ottawa Scale (NOS), with all scoring ≥ 7. Meta-analyses calculated pooled standardized mean differences (SMDs) for AMH and INHB levels, with subgroup analyses stratified by geographic region, BMI category, and age. Meta-regression analyzed the effects of these factors on AMH levels; sensitivity analyses and publication bias assessments verified result robustness.
resultsObese PCOS women had significantly lower serum AMH (SMD: -0.16; 95% CI: -0.29 to -0.02; P=0.02; I²=86%) and INHB (SMD: -0.98; 95% CI: -1.60 to -0.36; P=0.002; I²=90%) than non-obese counterparts. Meta-regression found no significant associations between AMH levels and geography (P=0.6516), BMI (P=0.2598), or age (P=0.5353). Subgroup analyses showed the most pronounced AMH differences in BMI ≤28 kg/m² (P=0.01) and ≥18-year-old (P=0.02) subgroups, with reduced heterogeneity here. AMH results were stable in sensitivity analysis, while INHB findings relied on a single study; funnel plot asymmetry suggested potential publication bias for AMH studies.
conclusionObesity correlates with markedly reduced AMH and INHB in PCOS, indicating metabolic impacts on ovarian reserve biomarkers. These findings highlight the need for weight-stratified interpretation of such markers and further investigation into obesity-related mechanisms in PCOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.